Meeting
2023 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer.
Authors
Paul Eliezer Oberstein
NYU Langone Health, New York, NY;
Paul Eliezer Oberstein , Cathy Eng , Eric Van Cutsem , Elena Elez , Michel Ducreux , Sejal Patel , Dona Pang , Leann Milford , Ryota Iwasawa , Robert W. Schnepp , Roland Knoblauch , Meena Thayu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05379595
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS279)
DOI
10.1200/JCO.2023.41.4_suppl.TPS279
Abstract #
TPS279
Poster Bd #
Q1
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
First Author: John H. Strickler
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2011 ASCO Annual Meeting
Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.
First Author: B. Chibaudel
![PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. .](https://d201v5jt9ylckg.cloudfront.net/102/6682/61160/61160_poster_pv.jpg)
First Author: J. Maurel